Skip to main content

Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Publication ,  Journal Article
Wood, DE; Kazerooni, EA; Baum, SL; Eapen, GA; Ettinger, DS; Hou, L; Jackman, DM; Klippenstein, D; Kumar, R; Lackner, RP; Leard, LE; Lennes, IT ...
Published in: J Natl Compr Canc Netw
April 2018

Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide. Early detection of lung cancer is an important opportunity for decreasing mortality. Data support using low-dose computed tomography (LDCT) of the chest to screen select patients who are at high risk for lung cancer. Lung screening is covered under the Affordable Care Act for individuals with high-risk factors. The Centers for Medicare & Medicaid Services (CMS) covers annual screening LDCT for appropriate Medicare beneficiaries at high risk for lung cancer if they also receive counseling and participate in shared decision-making before screening. The complete version of the NCCN Guidelines for Lung Cancer Screening provides recommendations for initial and subsequent LDCT screening and provides more detail about LDCT screening. This manuscript focuses on identifying patients at high risk for lung cancer who are candidates for LDCT of the chest and on evaluating initial screening findings.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

April 2018

Volume

16

Issue

4

Start / End Page

412 / 441

Location

United States

Related Subject Headings

  • United States
  • Tumor Burden
  • Tomography, X-Ray Computed
  • Risk Factors
  • Risk Assessment
  • Reproducibility of Results
  • Randomized Controlled Trials as Topic
  • Oncology & Carcinogenesis
  • Multimodal Imaging
  • Mass Screening
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wood, D. E., Kazerooni, E. A., Baum, S. L., Eapen, G. A., Ettinger, D. S., Hou, L., … Hughes, M. (2018). Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 16(4), 412–441. https://doi.org/10.6004/jnccn.2018.0020
Wood, Douglas E., Ella A. Kazerooni, Scott L. Baum, George A. Eapen, David S. Ettinger, Lifang Hou, David M. Jackman, et al. “Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw 16, no. 4 (April 2018): 412–41. https://doi.org/10.6004/jnccn.2018.0020.
Wood DE, Kazerooni EA, Baum SL, Eapen GA, Ettinger DS, Hou L, et al. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Apr;16(4):412–41.
Wood, Douglas E., et al. “Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw, vol. 16, no. 4, Apr. 2018, pp. 412–41. Pubmed, doi:10.6004/jnccn.2018.0020.
Wood DE, Kazerooni EA, Baum SL, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Lennes IT, Leung ANC, Makani SS, Massion PP, Mazzone P, Merritt RE, Meyers BF, Midthun DE, Pipavath S, Pratt C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Schiebler ML, Tong BC, Travis WD, Wei B, Yang SC, Gregory KM, Hughes M. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Apr;16(4):412–441.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

April 2018

Volume

16

Issue

4

Start / End Page

412 / 441

Location

United States

Related Subject Headings

  • United States
  • Tumor Burden
  • Tomography, X-Ray Computed
  • Risk Factors
  • Risk Assessment
  • Reproducibility of Results
  • Randomized Controlled Trials as Topic
  • Oncology & Carcinogenesis
  • Multimodal Imaging
  • Mass Screening